An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes |
| |
| Authors: | Jingbo Hu Chunlin Yang Hongbo Wang Jing Li Xueying Tan Jinhui Wang |
| |
| Affiliation: | 1. Institute of Drug Discovery Technology, Ningbo University, Ningbo, Chinahujiaabo@zju.edu.cn;3. Department of pharmacy, Ningbo University affiliated Yangming Hospital, Yuyao, China;4. College of pharmacy, Zhejiang Pharmaceutical College, Ningbo, China;5. Institute of Drug Discovery Technology, Ningbo University, Ningbo, China |
| |
| Abstract: | ![]()
ABSTRACTIntroduction: A growth in the market for anti-diabetic drugs, along with an ever-increasing population suffering from type 2 diabetes mellitus (T2DM), requires a critical re-evaluation of anti-diabetic drugs used for a long time, in order to provide up-to-date practical prescribing information for clinicians. Alogliptin benzoate was firstly approved in 2010 in Japan for T2DM, both as a monotherapy or in combination with other anti-diabetic drugs.Areas covered: This article provides a comprehensive review of the latest data on alogliptin benzoate, including hypoglycemic activity and safety.Expert opinion: The cumulative evidence for alogliptin benzoate is robust with regards to glycemic efficacy and safety. Low hypoglycemia risks and weight changes support its consideration as a first-line medication for T2DM, either as a monotherapy or in combination therapy with other anti-diabetic drugs such as metformin. Ongoing trials will look to better analyze and address its safety and efficacy in pediatric patients and expand our clinical knowledge of this medication. |
| |
| Keywords: | DPP-4 inhibitor alogliptin benzoate type 2 diabetes mellitus up-to-date evaluation |
|
|
